Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S470000, C546S268400, C546S284100, C549S467000
Reexamination Certificate
active
07153871
ABSTRACT:
PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II:wherein R1, R2, R3, R4, R7and R8are as defined herein.
REFERENCES:
patent: 5591776 (1997-01-01), Cavalla et al.
patent: 5622977 (1997-04-01), Warrellow et al.
patent: 5633257 (1997-05-01), Warrellow et al.
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5693659 (1997-12-01), Head et al.
patent: 5698711 (1997-12-01), Palfreyman
patent: 5710160 (1998-01-01), Guay et al.
patent: 5710170 (1998-01-01), Guay et al.
patent: 5712298 (1998-01-01), Amschler
patent: 5723460 (1998-03-01), Warrellow et al.
patent: 5728712 (1998-03-01), Montana et al.
patent: 5739144 (1998-04-01), Warrellow et al.
patent: 5776958 (1998-07-01), Warrellow et al.
patent: 5780477 (1998-07-01), Head et al.
patent: 5780478 (1998-07-01), Alexander et al.
patent: 5786354 (1998-07-01), Warrellow et al.
patent: 5798373 (1998-08-01), Warrellow et al.
patent: 5814651 (1998-09-01), Duplantier et al.
patent: 5840724 (1998-11-01), Fenton et al.
patent: 5849770 (1998-12-01), Head et al.
patent: 5859034 (1999-01-01), Warrellow et al.
patent: 5866593 (1999-02-01), Warrellow et al.
patent: 5880135 (1999-03-01), Gully et al.
patent: 5889014 (1999-03-01), Cavalla et al.
patent: 5891896 (1999-04-01), Warrellow et al.
patent: 5919937 (1999-07-01), Lynch et al.
patent: 5935978 (1999-08-01), Fenton et al.
patent: 5962483 (1999-10-01), Warrellow et al.
patent: 5962492 (1999-10-01), Warrellow et al.
patent: 6040329 (2000-03-01), Marfat
patent: 6077854 (2000-06-01), Warrellow et al.
patent: 6096768 (2000-08-01), Ashton et al.
patent: 6153630 (2000-11-01), Cavalla et al.
patent: 6162830 (2000-12-01), Connor et al.
patent: 6180650 (2001-01-01), Frenette et al.
patent: 6200993 (2001-03-01), Cote et al.
patent: 6204275 (2001-03-01), Friesen et al.
patent: 6245774 (2001-06-01), Warrellow et al.
patent: 6255326 (2001-07-01), Ashton et al.
patent: 6262040 (2001-07-01), Marfat
patent: 6297264 (2001-10-01), Head et al.
patent: 6699890 (2004-03-01), Schumacher et al.
patent: 2002/0151566 (2002-10-01), Schumacher et al.
patent: 2004/0152902 (2004-08-01), Schumacher et al.
patent: 2005/0119225 (2005-06-01), Schumacher et al.
patent: 0994100 (2000-04-01), None
patent: 1116711 (2001-07-01), None
patent: 2729142 (1996-07-01), None
patent: 11-189577 (1999-07-01), None
patent: 2001 011047 (2001-01-01), None
patent: WO 93/25517 (1993-12-01), None
patent: WO 94/02465 (1994-02-01), None
patent: WO 94/14742 (1994-07-01), None
patent: WO 94/27971 (1994-12-01), None
patent: WO 95/01338 (1995-01-01), None
patent: WO 96 21435 (1996-07-01), None
patent: WO 96/21435 (1996-07-01), None
patent: WO 96/23754 (1996-08-01), None
patent: WO 96/36620 (1996-11-01), None
patent: WO 97 00868 (1997-01-01), None
patent: WO 97 49702 (1997-12-01), None
patent: WO 98 09961 (1998-03-01), None
patent: WO 98/58901 (1998-12-01), None
patent: WO 99/33806 (1999-07-01), None
patent: WO 00/64874 (2000-11-01), None
patent: WO 00 69841 (2000-11-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 01/70738 (2001-09-01), None
patent: WO 02 059110 (2002-08-01), None
patent: WO 02 074726 (2002-09-01), None
Golub et al., Science, 286, 531-537, Oct. 15, 1999.
McGarry et al., Bioorganic and Medicinal Chemistry, 7, 1131-1139, 1999.
Piaz et al., Eur. J. Med. Chem., 35, 463-480, 2000.
Barnes, Peter J., Am. J. Respir. Crit. Care Med., 160, S72-S79, 1999.
Giembycz, Mark A., Drugs, 59(2), 193-212, Feb. 2000.
Heilman et al, “Synthesis and Antiinflammatory Evaluation of Substitued Isophthalonitriles, Trimesonitriles, Benzonitriles, and Terephthalonitriles”, Journal of Medicinal Chemistry, 1978, vol. 21, No. 9, pp. 906-913, XP-002226236.
Watanabe et al, “Structure-Activity Relationship and Rational Design of 3,4-Dephostatin Derivatives as Protein Tyrosine Phosphatase Inhibitors”, Pergamon Tetrahedron, 2000, vol. 56, pp. 741-752.
Inoue et al, “Steric Tuning in Chiral Ligand Mediated Enantioselective Alkylation of Imines”, Tetrahedron: Asymmetry, 1993, vol. 4, No.7, pp. 1603-1606, XP002226237.
Thomas C. McKenzie et al., “The Gomberg-Bachmann Reaction of Purines”,J. Heterocyclic Chem., May-Jun. 1987, pp. 859-861, vol. 24.
Vasu Nair et al., “Novel, Stable Congeners of Antiretroviral Compound 2′, 3′-Dideoxyadenosine,”J. Am. Chem. Soc., 1989, pp. 8502-8504, vol. 111.
Vasu Nair et al., “Synthesis Of Congeners Of Adenosine Resistant To Deamination By Adenosine Deaminase,”J. Chem. Soc Comm., 1989, pp. 878-879.
James L. Kelley et al., “Synthesis and Structure- Activity Relationships of 2-Substituted-6-(dimethylamino)-9-(4-methylbenzyl)-9H-purines with Antirhinovirus Activity,”J. Med. Chem., 1989, pp. 218-224, vol. 32.
James E. Kelley et al., “Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines,”Eur. J. Med. Chem., 1990, pp. 131-135, vol. 25.
Roger J. Schilling et al., “A High-Throughput Assay For Cyclic Nucleotide Phosphodiesterases,”Analytical Biochemistry, 1994, pp. 154-158, vol. 215.
Donald V. Daniels et al., “A Semiautomated Method for the Assay of Cyclic Adenosine 5′-Monophosphate Phosphodiesterase,”Analytical Biochemistry, 1996, pp. 367-369, vol. 236.
Jean-Jacques Bourguignon et al., “9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors,”J. Med. Chem, 1997, pp. 1768-1770, vol. 40.
James L. Kelley et al., “6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents,”J. Med. Chem., 1997, pp. 3207-3216, vol. 40.
Hiroyuki Sawanishi et al., “Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines”,J. Med. Chem., 1997, pp. 3248-3253, vol. 40.
J.E. Sounnes et al., “Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases”,Cell Signal, 1997, pp. 227-236. vol. 9, No. 3-4.
Mary Elizabeth Bach et al., “Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long term potentiationin vitroand are attenuated by drugs that enhance the cAMP signaling pathway”,Proc. Natl. Acad. Sci. USA, Apr. 1999, pp. 5280-5285, vol. 96.
Elisabeth Boichot et al., “Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine,”The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, vol. 292, No. 2.
Anil S. Guram et al., “A Simple Catalytic Method for the conversion of Aryl Bromides to Arylamines,” Angew. Chem. Int, Ed. Engl., 1995, vol. 34, No. 12, pp. 1348-1350.
Michael S. Driver et al., “A Second-Generation Catalyst for the Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdC12, ” J. Am. Chem. Soc., 1996, vol. 118, pp. 7217-7218.
Takashi Egawa et al., “Rolipram and its Optical Isomers, Phosphodiesterase 4 Inhibitors, Attenuated the Scopolamine-Induced Impairments of Learning and Memory in Rats,” J. Pharmacol., vol. 75, 275-281(1997).
Peng Wang et al., “Expression, Purification, and Characterization of Human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D,”Biochem. And Biophys. Research Comm., vol. 234, 320-324 (1997).
Domine M. T. Chan et al., “New N- abd O-Arylations with Phenylboronic Acids and Cupric Acetate,” Tetrahedron Letters, vol. 39, 2933-2936 (1998).
Mark Barad et al., “Rolipram, a Type IV-Specific Phosphodiesterase Inhibitor Facillitates the Establishment of Long-lasting Long-term Potentiation and Improves Memory,” Proc. Natl. Acad. Sci., vol. 95, pp. 15020-15025 (Dec. 1998).
Miles D. Houslay et al., “The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family: Intracelllular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-in
Hopper Allen T.
Schumacher Richard A.
Tehim Ashok
Memory Pharmaceuticals Corporation
Millen White Zelano & Branigan P.C.
Powers Fiona T.
LandOfFree
Phosphodiesterase 4 inhibitors, including aminoindazole and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphodiesterase 4 inhibitors, including aminoindazole and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiesterase 4 inhibitors, including aminoindazole and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719666